Trials / NCT05748873
Promising ROd-cone DYstrophy Gene therapY
Underway, not enrolling Phase 1 / Phase 2 Gene therapy
- Sponsor
- SparingVision
- Treatment
- SPVN06
- Gene
- PDE6A, PDE6B, RHO
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 33 participants
- Started
- 2023-04-12
- Main results expected
- 2027-02
- Results posted
- Not yet
- Record last updated
- 2026-05-15
What the study is testing
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).
Where it runs
France (1)
- CHNO XV-XX Paris - CIC 1423, Paris
United States (5)
- Bascom Palmer Eye Institute/University of Miami, Miami, Florida
- Mass Eye and Ear, Boston, Massachusetts
- Casey Eye Institute, Portland, Oregon
- UPMC Eye Center, Pittsburgh, Pennsylvania
- Retina Foundation of the Southwest, Dallas, Texas